COVID-19 PANDEMIC Urgent referrals for suspected cancer were down 60% in April in the UK; some cancer types were differentially affected with suspected breast cancer referrals down 78%.

These reports present the validated results of the monitoring of waiting times for cancer services in England and the information on the number of people who attended outpatient appointments within two weeks of an urgent referral by their GP for suspected cancer or breast symptoms and, for patients with cancer, on the numbers who started treatment within 31 and 62 days are included for each organisation. The numbers who started some types of subsequent treatments within 31 days are also given for each organisation. Numbers of patients who were not seen or treated within the specified times are also included.

Please note that: (this has included revisions)

Waiting times for suspected and diagnosed cancer patients for 04 2020 (Official Statistics);

Waiting times for suspected and diagnosed cancer patients, Q1 2020-21 (Provider based – National Statistics);

Waiting times for suspected and diagnosed cancer patients, Q1 2020-21 (Commissioner based – Official Statistics).

National and official statistics are produced impartially and free from political influence.

You may also be interested in these resources

Scientific Application Note

DRUG TARGETS: A novel ATR inhibitor has cleared phase I development with manageable toxicity; responses were seen in tumours harbouring ATM/ARID1A and BRCA1 alteration (colorectal and ovarian respectively)

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors Published online June 22, 2020. AbstractPURPOSE Preclinical studies demonstrated that ATR inhibition can...

Scientific Application Note

LUNG CANCER: The FDA have approved the MET inhibitor capmatinib for advanced NSCLC harbouring MET exon 14 skipping. Approval is based on ORR of 68% and 41% for treatment-naive and previously treated patients, respectively

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell...

Share This